Growth hormone therapy before and after pediatric renal transplant

Pediatric Transplantation

Volumn 7, Issue 6, 2003, Pages 426-440

  Acott, Philip D ^a,b   Pernica, Jeffrey M ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Growth hormone; Pediatric renal diseases; Renal transplant

Indexed keywords

CORTICOSTEROID; DACLIZUMAB; GLUCOCORTICOID; GROWTH HORMONE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; SOMATOMEDIN C; STEROID; TACROLIMUS;

ACUTE GRAFT REJECTION; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; AVASCULAR NECROSIS; B LYMPHOCYTE; BIOAVAILABILITY; BRAIN PSEUDOTUMOR; CAUSE OF DEATH; CHRONIC KIDNEY FAILURE; CLINICAL FEATURE; CLINICAL TRIAL; CYSTINOSIS; DIETARY INTAKE; DISEASE EXACERBATION; DOSE RESPONSE; DOWN REGULATION; DRUG HALF LIFE; DRUG POTENCY; DRUG SCREENING; EXHAUSTION; FOLLOW UP; GLOMERULOSCLEROSIS; GLUCOSE INTOLERANCE; GRAFT FAILURE; GRAFT REJECTION; GROWTH; GROWTH INHIBITION; HORMONAL REGULATION; HORMONAL THERAPY; HORMONE URINE LEVEL; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERPARATHYROIDISM; KIDNEY ALLOGRAFT; KIDNEY FAILURE; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY HYPERTROPHY; LEUKEMIA; LYMPHOPROLIFERATIVE DISEASE; NONHUMAN; PAPILLEDEMA; PARATHYROID HYPERPLASIA; PERTHES DISEASE; RENAL OSTEODYSTROPHY; REVIEW; RISK; SCOLIOSIS; SIDE EFFECT; STEROID THERAPY; SURVIVAL RATE; TREATMENT WITHDRAWAL; ULTRAFILTRATION; UREMIA;

CHILD; CHILD DEVELOPMENT; HUMAN GROWTH HORMONE; HUMANS; KIDNEY TRANSPLANTATION; PEDIATRICS; RANDOMIZED CONTROLLED TRIALS; RECOMBINANT PROTEINS;

EID: 0344413636     PISSN: 13973142     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1397-3142.2003.00108.x     Document Type: Review

References (137)

1. BENFIELD MR, MCDONALD R, SULLIVAN EK, et al. The 1997 Annual Renal Transplantation in Children: Report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Pediatr Tansplant 1999: 2: 152-167.
2. TONSHOFF B, HAFFNER D, MEHLS O, et al. Efficacy and safety of growth hormone treatment in short children with renal allografts: three year experience. Kidney Int 1993: 44: 199-207.
3. HAFFNER D, SCHAEFER F, GIRARD J, et al. Metabolic clearance of recombinant human growth hormone in health and chronic renal failure. J Clin Invest 1994: 93: 1163-1171.
4. SCHAEFER F, BAUMANN G, HAFFNER D, et al. Multifactorial control of the elimination kinetics of unbound (free) growth hormone (GH) in the human: regulation by age, adiposity, renal function, and steady state concentrations of GH in plasma. J Clin Endocrinol Metab 1996: 119: 568-577.
5. TONSHOFF B, VELDHUIS JD, HEINRICH U, MEHLS O. Deconvolutional analysis of spontaneous nocturnal growth hormone secretion in prepubertal children with preterminal chronic renal failure and with end-stage renal disease. Pediatr Res 1995: 37: 86-93
6. VELDHUIS JD, IRANMANESH A, WILKOWSKI MJ, SAMOJLIK E. Neuroendocrine alterations in the somatotropic and lactotropic axes in uremic men. Eur J Endocrinol 1994: 131: 489-498
7. SCHAEFER F, VELDHUIS JD, STANHOPE R, JONES J, SCHARER K. Alterations in growth hormone secretion and clearance in peripubertal boys with chronic renal failure and after renal transplantation. Cooperative Study Group of Pubertal development in Chronic Renal Failure. J Clin Endocrinol Metab 1994: 78: 1298-1306
8. MEHLS O, WUHL E, HAFFNER D, SCHAEFER F, TONSHOFF B. Growth hormone treatment of short children with chronic renal failure before and after renal transplantation: rationale and recent results. Nephrol Dial Transplant 1996: 11: 1747-1750.
9. BERARD E, CROSNIER H, SIX-BENETON A, CHEVALLIER T, COCHAT P, BROYER M. Recombinant human growth hormone treatment of children on hemodialysis. Pediatr Nephrol 1998: 12: 304-310.
10. TONSHOFF B, CRONIN MJ, REICHERT M, et al. Reduced concentration of serum growth hormone (GH)-binding protein in children with chronic renal failure: correlation with GH insensitivity. J Clin Endocrinol Metab 1997: 82: 1007-1013.
11. MARTHA Jr PM, ROGOL AD, BLIZZARD RM, SHAW MA, BAUMANN G. Growth hormone-binding activity is inversely related to 24-hour growth hormone release in normal boys. J Clin Endocrinol Metab 1991: 73: 175-181.
12. TONSHOFF B, BLUM WF, MEHLS O. Derangements of the somatotropic hormone axis in chronic renal failure. Kidney Int 1997: 51 (Suppl. 58): S106-S113.
13. POWELL DR, DURHAM SK, LIU F, et al. The insulin-like growth factor axis and growth in children with chronic renal failure: a report of the Southwest Pediatric Nephrology Study Group. J Clin Endocrinol Metab 1998: 83: 1654-1661.
14. RITVOS O, RANTA T, JALKANEN J, et al. Insulin-like growth factor (IGF) binding protein from human decidua inhibits the binding and biological action of IGF-I in cultured choriocarcinoma cells. Endocrinology 1988: 122: 2150-2157.
15. BURCH WM, CORREA J, SHIVELY JE, POWELL DR. The 25-kilodalton insulin-like growth factor (IGF)-binding protein inhibits both basal and IGF-I mediated growth of chick embryo pelvic cartilages in vitro. J Clin Endocrinol Metab 1990: 70: 173-180.
16. BINOUX M, HOSSENLOPP P. Insulin-like growth factor (IGF) and IGF-binding proteins: comparison of human serum and lymph. J Clin Endocrinol Metab 1988: 67: 509-514.
17. TONSHOFF B, BLUM WF, MEHLS O. Serum insulin-like growth factors (IGFs) and IGF binding protein-1, -2, and -3 in children with end-stage renal failure. Pediatr Nephrol 1996: 10: 269-274.
18. TONSHOFF B, BLUM WF, WINGEN A, MEHLS O. Serum insulin-like growth factors (IGFs) and IGF binding proteins 1, 2 and 3 in children with chronic renal failure: relationship to height and glomerular filtration rate. J Clin Endocrinol Metab 1995: 80: 2684-2691.
19. BLUM WF, RANKE MB, KIETZMANN K, TONSHOFF B, MEHLS O. Growth hormone resistance and inhibition of somatomedin activity by excess of insulin-like growth factor binding protein in uremia. Pediatr Nephrol 1991: 5: 539-544.
20. BAXTER RC. IGF binding protein-3 and the acid-labile subunit: formation of the ternary complex in vitro and in vivo. In: LEROITH D, RAIZADA MK, eds. Current Directions in Insulin-like Growth Factor Research, New York: Plenum Press, 1993, pp. 237.
21. DING H, GAO XL, HIRSCHBERG R, VADGAMA JV, KOPPLE JD. Impaired actions of insulin-like growth factor 1 on protein synthesis and degradation in skeletal muscle of rats with chronic renal failure. Evidence for a postreceptor defect. J Clin Invest 1996: 97: 1064-1075.
22. ISLEY WL, UNDERWOOD LE, CLEMMONS DR. Dietary components that regulate serum somatomedin-C concentration in humans. J Clin Invest 1983: 71: 175-182.
23. MUSEY VC, GOLDSTEIN S, FARMER PK, MOORE PB, PHILLIPS LS. Differential regulation of IGF-I and IGF-binding protein-1 by dietary composition in humans. Am J Med Sci 1993: 305: 131-138.
24. ZAMBONI G, DUFILLOT D, ANTONIAZZI F, VALENTINI R, GENDREL D, TATO L. Growth hormone-binding proteins and insulin-like growth factor-binding proteins in protein-energy malnutrition, before and after nutritional rehabilitation. Pediatr Res 1996: 39: 410-414.
25. LEMOZY S, PUCILOWSKA JB, UNDERWOOD LE. Reduction of insulin-like growth factor-1 (IGF-I) in protein-restricted rats is associated with differential regulation of IGF-binding protein messenger ribonucleic acids in liver and kidney, and peptides in liver and serum. Endocrinology 1994: 135: 617-623.
26. HILL DJ. Effects of cortisol on cell proliferation and proteoglycan synthesis and degradation incartilage zones of the calf costochondral growth plate in vitro with and without plasma somatomedin activity. J Endocrinol 1981: 88: 425-430.
27. CHYUN YS, KREAM BE, RAISZ LG. Cortisol decreases bone formation by inhibiting periosteal cell proliferation. Endocrinol 1984: 114: 477-481.
28. DEARDEN LC, MOSIER HD Jr. The effect of prolonged prednisone treatment on human costal cartilage. Am J Pathol 1975: 81: 267-282.
29. HYMANS JS, MOORE RE, LEICHTNER AM, CAREY DE, GOLDBERG BD. Relationship of type I procollagen to corticosteroid therapy in children with inflammatory bowel disease. J Pediatr 1988: 112: 893-898.
30. HYAMS JS, CAREY DE. Corticosteroids and growth. J Pediatr 1988: 113: 249-254.
31. GOURMELIN M, GIRARD F, BINOUX M. Serum somatomedin insulin-like growth factor (IGF) and IGF carrier levels in patients with Cushing's syndrome or receiving glucocorticoid therapy. J Clin Endocrinol Metab 1982: 54: 885-892.
32. UNTERMAN TG, PHILIPS LS. Glucocorticoid effects on somatomedins and somatomedin inhbitors. J Clin Endocrinol Metab 1985: 61: 618-626.
33. TONSHOFF B, MEHLS O. Interaction between glucocorticoids and the somatotrophic axis. Acta Paediatr 1996: 417 (Suppl.): 72-75.
34. MAXWELL H, HAFFNER D, REES L. Catch-up growth occurs after renal transplantation in children of pubertal age. J Pediatr 1998: 133: 435-440.
35. BROYER M, GUEST G, GAGNADOUX MF. Growth rate in children receiving alternate-day corticosteroid treatment after kidney transplantation. J Pediatr 1992: 120: 721-725.
36. HOKKEN-KOELEGA ACS, VAN ZAAL MAE, DE RIDDER MAJ, et al. Growth after renal transplantation in prepubertal children: impact of various treatment modalities. Ped Res 1994: 35: 367-371.
37. POTTER DE. Alternate-day versus daily corticosteroid therapy in transplanted children. In: SCHARER K, ed. Growth and Endocrine Changes in Children and Adolescents with Chronic Renal Failure, Vol 20. Pediatric Adolescent Endocrinology. Basel: Karger, 1989, pp. 126-135.
38. JABS K, SULLIVAN EK, AVNER ED, HARMON WE. Alternateday steroid dosing improves growth without adversely affecting survival or long-term graft function. A report of the North American Pediatric Renal Transplant Cooperative Study. Transplantation 1996: 61: 31-36.
39. TEJANI A, BUTT KMH, RAJPOOT D, et al. Strategies for optimizing growth in children with kidney transplants. Transplantation 1989: 47: 229-233.
40. KAISER BA, POLINSKY MS, PALMER JA, et al. Growth after conversion to alternate-day corticosteroids in children with renal transplants: a single-center study. Pediatr Nephrol 1994: 8: 320-325.
41. KLAUS G, JECK N, KONRAD M, FORSTER B, SOERGEL M. Risk of steroid withdrawal in pediatric renal transplant patients with suspected steroid toxicity. Clin Nephrol 2001: 56: S37-S42.
42. SARWAL MM, YORGIN PD, ALEXANDER S, et al. Promising early outcomes with a novel, complete steroid avoidance immunosuppression protocol in pediatric renal transplantation. Transplantation 2001: 72: 13-21.
43. HOKKEN-KOELEGA ACS, STIJNEN T, DE RIDDER MAJ, et al. Growth hormone treatment in growth-retarded adolescents after renal transplant. Lancet 1994: 343: 1313-1317.
44. FERRARIS JR, PENNISI P, PASQUALINI T, JASPER H. Effects of deflazacort immunosuppression on long-term growth and growth factors after renal transplantation. Pediatr Nephrol 1997: 11: 322-324.
45. FERRARIS JR, PASQUALINI T, LEGAL S, et al. Effect of deflazacort versus mehtylprednisolone on growth, body composition, lipid profile, and bone mass after renal transplantation. The Deflazacort Study Group. Pediatr Nephrolo 2000: 14: 682-688.
46. TONSHOFF B, MEHLS O. Factors affecting growth and strategies for treatment in children after renal transplantation. Pediatr Transplantation 1997: 1: 176-82.
47. HAFFNER D, SCHAEFER F, NISSEL R, WUHL E, TONSHOFF B, MEHLS O. Effect of growth hormone treatment on the adult height of children with chronic renal failure. N Engl J Med 2000: 343: 923-30.
48. FINE RN, KOHAUT EC, BROWN D, PERLMAN AJ. Growth after recombinant human growth hormone treatment in children with chronic renal failure: report of a multicenter randomized double-blind placebo-controlled study. J Pediatr 1994: 124: 374-382.
49. SCHAEFER F, MEHLS O. Endocrine, metabolic, and growth disorders. In: HOLLIDAY MA, BARRAT TM, AVNER ED, eds. Pediatric Nephrology. Williams & Wilkins, Baltimore, 1994, 1241-1286.
50. MAK RHK, HAYCOCK GB, CHANTLER C. Glucose intolerance in children with chronic renal failure. Kidney Int 1993: 24 (Suppl. 15): 22-26.
51. SMITH D, DEFRONZO RA. Insulin resistance in uremia is mediated by postbinding defects. Kidney Int 1982: 22: 54-62.
52. HAFFNER D, NISSLE R, WUHL E, et al. Metabolic effects of long-term growth hormone treatment in prepubertal children with chronic renal failure and after kidney transplantation. Pediatr Res 1998: 43: 209-215.
53. FINE RN, KOHAUT E, BROWN D, KUNTZE J, ATTIE KM. Long-term treatment of growth retarded children with chronic renal insufficiency, with recombinant human growth hormone. Kidney Int 1996: 49: 781-785.
54. WATANABE S, TSUNEMATSU Y, FUJIMOTO J, KOMIYAMA A. Leukaemia in patients treated with growth hormone (Letter). Lancet 1988: 21: 1159-1160.
55. ZADIK A, ESTROV Z, KAROV Y, HAHN T, BARAK Y. The effect of growth hormone and IGF-I on clonogenic growth of hematopoietic cells in leukemic patients during active disease and during remission. J Pediatr Endocrinol 1993: 6: 79-83.
56. BECHENSTEEN AG, HALVORSEN S, ABDELNOOR M, SKOTTNER A. Growth hormone treatment and development of malignancy: recombinant human growth hormone does not induce leukemia in AKR/O mice. Pediatr Hematol Oncol 1993: 10: 41-47.
57. FRADKIN JE, MILLS JL, SCHONBERGER LB, et al. Risk of leukemia after treatment with pituitary growth hormone. JAMA 1993: 270: 2829-2832.
58. STAHNKE N. Leukemia in growth hormone-treated patients: an update, 1992. Horm Res 1992: 38 (Suppl. 1): 56-62.
59. ALLEN D. Safety of human growth hormone therapy: current topics. J Pediatr 1996: 128: S8-S13.
60. KAUFMAN DB. Growth hormone and renal osteodystrophy: a case report. Pediatr Nephrol 1998: 12: 157-159.
61. OGLE G, ROSENBERG A, KAINER G. Renal effects of growth hormone. II. Electrolyte homeostasis and body composition. Pediatr Nephrol 1992: 6: 483-489.
62. CHUNG SMK, BATTERMAN SC, BRIGHTON CT. Shear strength of the human femoral capital epiphyseal plate. J Bone Joint Surg Am 1976: 58A: 94-103.
63. CHUNG SMK. Diseases of the developing hip joint. Pediatr Clin North Am 1986: 33: 1457-1473.
64. FIDLER MW, BROOK CGD. Slipped upper femoral epiphysis following treatment with human growth hormone. J Bone Joint Surg Am 1974: 56B: 1719-1722.
65. HEATLEY FW, GREENWOOD RH, BOASE DL. Slipping of the upper femoral epiphyses in patients with intracranial tumours causing hypopituitarism and chiasmal compression. J Bone Joint Surg Am 1976: 58B: 169-175.
66. RAPPAPORT EB, FIFE D. Slipped capital femoral epiphysis in growth hormone-deficient patients. Am J Dis Child 1985: 139: 396-399.
67. RENNIE W, MITCHELL N. Slipped femoral capital epiphysis occurring during growth hormone therapy. J Bone Joint Surg Am 1974: 56B: 703-705.
68. MEHLS O, RITZ E, KREMPIEN B, et al. Slipped epiphyses in renal osteodystrophy. Arch Dis Child 1975: 50: 545-554.
69. BLETHEN SL, RUNDLE AC. Slipped capital femoral epiphysis in children treated with growth hormone. A summary of the National Cooperative Growth Study experience. Horm Res 1996: 46: 113-116.
70. MEHLS O, RITZ E, OPPERMANN HC, GUIGNARD JP. Femoral head necrosis in uremic children without steroid treatment or transplantation. J Pediatr 1981: 99: 926-929.
71. BOECHAT MI, WINTERS WD, HOGG RJ, FINE RN, WATKINS SL. Avascular necrosis of the femoral head in children with chronic renal disease. Radiology 2001: 218: 411-413.
72. CLAYTON PE, COWELL CT. Safety issues in children and adolescents during growth hormone therapy - a review. Growth Horm IGF Res 2001: 10: 196-197.
73. VIDIL A, JOURNEAU P, SOULIE A, PADOVANI JP, POULIQUEN JC. Evolution of scoliosis in six children treated with growth hormone. J Pediatr Orthop B 2001: 10: 197-200.
74. MANEATIS T, BAPTISTA J, CONNELLY K, BLETHEN S. Growth hormone safety update from the National Cooperative Growth Study. J Pediatr Endocrinol Metab 2000: 13: 1035-1044.
75. BABIKIAN P, CORBETT J, BELL W. Idiopathic intracranial hypertension in children: the Iowa experience. J Child Neurol 1994: 9: 144-149.
76. MALOZOWSKI S, TANNER LA, WYSOWSKI DK, et al. Benign intracranial hypertension in children with growth hormone deficiency treated with growth hormone. J Pediatr 1995: 126: 996-999.
77. LESSELL S. Pediatric pseudotumor cerebri (idiopathic intracranial hypertension). Surv Ophthalmol 1992: 37: 155-166.
78. DHIRAVIBULYA K, OUVRIER R, JOHNSTON I, et al. Benign intracranial hypertension in childhood: a review of 23 patients. J Paediatr Child Health 1991: 27: 304-307.
79. PHILLIPS PH, REPKA MX, LAMBERT SR. Pseudotumor cerebri in children. J AAPOS 1988: 2: 33-38.
80. SPITERI MA, JAMES DG. Adverse ocular reactions to drugs. Postgrad Med J 1983: 59: 343-349.
81. KOLLER EA, STADEL BV, MALOZOWSKI SN. Papilledema in 15 renally compromised patients treated with growth hormone. Pediatr Nephrol 1997: 11: 451-454.
82. ROGERS AH, ROGERS GL, BREMER DL, MCGREGOR ML. Pseudotumor cerebri in children receiving recombinant human growth hormone. Ophthalmology 1999: 106: 1186-1189.
83. ARNOLD AC. Pseudotumor cerebri in children receiving recombinant human growth hormone (discussion). Ophthalmology 1999: 106: 1189-1190.
84. FINE RN, BROWN DF, KUNTZE J, WOOSTER P, KOHAUT EC. Growth after discontinuation of recombinant human growth hormone therapy in children with chronic renal insufficiency. J Pediatr 1996: 129: 883-891.
85. SIMON D, ROSILIO M, MAISIN A, et al. Post graft development of short children treated with growth hormone before kidney graft. Pediatr Nephrol 1999: 13: 723-729.
86. FINE RN, SULLIVAN EK, KUNTZE J, BLETHEN S, KOHAUT E. The impact of recombinant human growth hormone treatment during chronic renal insufficiency on renal transplant recipients. J Pediatr 2000: 136: 376-382.
87. POWELL DR, LIU F, BAKER BK, et al. Modulation of growth factors by growth hormone in children with chronic renal failure. Kidney Int 1997: 51: 1970-1979.
88. MAXWELL H, REES L. Randomised controlled trial of recombinant human growth hormone in prepubertal and pubertal renal transplant recipients. Arch Dis Child 1998: 79: 481-487.
89. GUEST G, BERARD E, CROSNIER H, CHEVALLIER T, RAPPAPORT R, BROYER M. Effects of growth hormone in short children after renal transplantation. Pediatr Nephrol 1998: 12: 437-446.
90. BENFIELD MR, PARKER KL, WALDO FB, OVERSTREET SL, KOHAUT EC. Treatment of growth failure in children after renal transplantation. Transplantation 1993: 55: 305-308.
91. VAN DOP C, JABS KL, DONOHOUE PA, BOCK GH, FIVUSH BA, HARMON WE. Accelerated growth rates in children treated with growth hormone after renal transplantation. J Pediatr 1992: 120: 244-250.
92. VAN ES A. Growth hormone treatment in short children with chronic renal failure and after renal transplantation: combined data from European clinical trials. Acta Paediatr Scand 1991: 379 (Suppl.): 42-48.
93. HAFFNER D, WUHL E, SCHAEFER F, NISSEL R, TONSHOFF B, MEHLS O. Factors predictive of the short- and long-term efficacy of growth hormone treatment in prepubertal children with chronic renal failure. J Am Soc Nephrol 1998: 9: 1899-1907.
94. SCHAEFER F, HAFFNER D, WUHL E, MEHLS O. Long-term experience with growth hormone treatment in children with chronic renal failure. Perit Dial Int 1999: 19 (Suppl. 2): S467-S472.
95. HOKKEN-KOELEGA ACS, STIJNEN T, DE JONG RCJW, et al. A placebo-controlled, double-blind trial of growth hormone treatment in prepubertal children after renal transplant. Kidney Int 1996: 49 (Suppl. 53): S128-S134.
96. FINE RN, YADIN O, MOULTEN L, NELSON PA, BOECHAT MI, LIPPE BH. Extended recombinant human growth hormone treatment after renal transplantation in children. J Am Soc Nephrol 1992: 2: S274-S283.
97. SCHWARTZ ID, WARADY BA, BUCHANAN CL, et al. 'Low-dose' growth hormone therapy during peritoneal dialysis or following renal transplantation. Pediatr Nephrol 1995: 9: 320-324.
98. LAINE J, KROGERUS L, SARNA S, JALANKO H, RONNHOLM K, HOLMBERG C. Recombinant human growth hormone treatment. Transplantation 1996: 61: 898-903.
99. TYDEN G, BERG U, REINHOLT F. Acute renal graft rejection after treatment with human growth hormone. Lancet 1990: 336: 1455-1456.
100. PANAYOTATOS N, RADZIEJEWSKA E, ACHESON A, et al. Localization of functional receptor epitopes on the structure of ciliary neurotrophic factor indicates a conserved, function related epitope topography among helical cytokines. J Biol Chem 1995: 270: 14007-14014.
101. MAXWELL H, DALTON RN, NAIR DR, et al. Effects of recombinant human growth hormone on renal function in children with renal transplants. J Pediatr 1996: 128: 177-183.
102. MENSTER M, BREEN TJ, SULLIVAN EK, FINE RN. Growth-hormone treatment of renal transplant recipients: the National Cooperative Growth Study experience - a report of the National Cooperative Growth Study and the North American Pediatric Renal Transplant Cooperative Study. J Pediatr 1997: 131: S20-S24.
103. BROYER M. Results and side-effects of treating children with growth hormone after kidney transplantation - a preliminary report. Acta Paediatr 1996: 417 (Suppl.): 76-79.
104. BADOLATO R, BOND HM, VALERIO G, et al. Differential expression of surface membrane growth hormone receptor on human peripheral blood lymphocytes detected by dual fluorochrome flow cytometry. J Clin Endocrinol Metab 1994: 79: 984-990.
105. KOOIJMAN R, SCHOLTENS LE, RIJKERS GT, ZEGERS BJ. Differential expression of type I insulin-like growth factor receptors in different stages of human T cells. Eur J Immunol 1995: 25: 931-935.
106. KOTZMANN H, KOLLER M, CZERNIN S, et al. Effect of elevated growth hormone concentrations on the phenotype and functions of human lymphocytes and natural killer cells. Neuroendocrinology 1994: 60: 618-625.
107. BENFIELD MR. Immunological consequences of growth hormone administration; relevance for renal transplantation. In: ANDREUCCI VE, FINE LG, eds. International yearbook of nephrology. Oxford: Oxford University Press, 1996: pp. 12.
108. SNOW EC, FELDBUSH TL, OAKS JA. The effect of growth hormone and insulin upon MLC responses and the generation of cytotoxic lymphocytes. J Immunol 1981: 126: 161-164.
109. GIUSTINA A, BUSSI AR, JACOBELLO C, WEHRENBERG WB. Effects of recombinant human grwoth hormone (GH) on bone and intermediary metabolism in patients receiving chronic glucocorticoid treatment with suppressed endogenous GH response to GH-releasing hormone. J Clin Endocrinol Metab 1995: 80: 122-129.
110. LEBL J, SEDIVA A, FRISCH H, RIEDL S, BALZAR E, KRASNICANOVA H. Lymphocyte subsets in renal transplant recipients during growth hormone therapy. Endocr Regul 1999: 33: 3-8.
111. MAXWELL H, AMLOT P, REES L. Growth hormone and markers of immune function in children with renal transplants. Pediatr Nephrol 2000: 14: 473-475.
112. HIRSCHBERG R, KOPPLE D. Effects of growth hormone on GFR and renal plasma flow in man. Kidney Int 1987: 32 (Suppl. 22): 21-24.
113. CORVILIAN J, ABRAMOW M, BERGANS A. Some effects of human growth hormone on renal haemodynamics and on tubular phosphate transport in man. J Clin Invest 1962: 41: 1230-1235.
114. HAFFNER D, RITZ E, MEHLS O, et al. Growth hormone induced rise in glomerular filtration rate is not obliterated by angiotensin-converting enzyme inhibitors. Nephron 1990: 55: 63-68.
115. ARNQUIST HJ, BALLERMANN BJ, KING GL. Receptors for and effects of insulin and IGF-I in rat glomerular mesangial cells. Am J Physiol 1988: 254: C411-C416.
116. KAWAGUCHI H, HATTORI M, ITO K. Somatic and renal effects of growthb hormone in rats with chronic renal failure. Pediatr Nephrol 1997: 11: 280-284.
117. ALLEN DB, FOGO A, EL-HAYEK R, LANGHOUGH R, FRIEDMAN AL. Effects of prolonged growth hormone administration in rats with chronic renal insufficiency. Pediatr Res 1992: 31: 406-410
118. MEHLS O, TITZ E, HUNZIKER EB, EGGKI O, HEIRICH U, ZAPF J. Improvement of growth and food utilization by human recombinant growth hirmone in uraemia. Kidney Int 1988: 33: 45-52.
119. POWELL Dr, ROSENFELD RG, HINTZ RL. Effects of growth hormone therapy and malnutrition on the growth of rats with renal failure. Pediatr Nephrol 1988: 2: 425-430.
120. DOI T, STRIKER L, QUAIFE L, et al. Progressive glomerulosclerosis develops in transgenic mice chronically expressing GH and GH RF but not in those expressing IGF-I. Am J Pathol 1990: 131: 398.
121. KAWAGUCHI H, ITOH K, MORI H, HAYASHI H, MAKINO S. Renal pathology in rats bearing tumour-secreting growth hormone. Pediatr Nephrol 1991: 5: 533-538.
122. CHRISTIANSEN JS, GAMMELGAARD J, ORSKOV H, ANDERSEN AR, TELMER S, PARVING HH. Kidney function and size in normal subjects before and during growth hormone administration for one week. Eur J Clin Inveset 1981: 11: 487-490.
123. PARVING HH, NOER I, MOGENSEN CE, SVENDSEN PA. Kidney function in normal man during short-term growth hormone infusion. Acta Endocrinol (Copenh) 1978: 89: 796-800.
124. HIRSCHBERG R, RABB H, BEGAMO R, KOPPLE JD. The delayed effect of growth hormone on renal function in humans. Kidney Int 1989: 35: 865-70.
125. THISSEN JP, KETELSLEGERS JM, UNDERWOOD LE. Nutritional regulation of the insulin-like growth factors. Endocr Rev 1994: 15: 80-101.
126. MAXWELL H, NAIR DR, DALTON RN, RIGDEN SPA, REES L. Differential effects of recombinant human growth hormone on glomerular filtration rate and renal plasma flow in chronic renal failure. Pediatr Nephrol 1995: 9: 458-463.
127. FENNEL RS, VAN DEUSEN J, RILEY WL. Steroid-induced diabetes in pediatric renaltransplant recipients. Pediatr Nephrol 1983: 4: 103-107.
128. FILLER G, AMENDT P, KOHNERT KD, DEVAUX S, EHRICH JH. Glucose tolerance and insulin secretion in children before and during recombinant growth hormone treatment. Horm Res 1998: 50: 32-37.
129. TYDEN G, WERNERSSON A, SANDBERG J, BERG U. Development of renal cell carcinoma in living donor kidney grafts. Transplantation 2000: 70: 1552-1553.
130. MEHLS O, WILTON P, LILIEN M, et al. Does growth hormone treatment affect the risk of post-transplant renal cancer? Pediatr Nephrol 2002: 17: 984-989.
131. LARON Z, WANG XL, KLINGER B. et al. Growth hormone treatment increases circulating lipoprotein(a) in children with chronic renal failure. J Pediatr Endocrinol Metab 1996: 9: 533-537.
132. DAHLEN GH. Lp(a) lipoprotein in cardiovascular disease (review). Atherosclerosis 1994: 108: 111-126.
133. UTERMANN G. The mysteries of lipoprotein(a) (review). Science 1989: 246: 904-910.
134. QUERFELD U, HAFFNER D, WUHL E, et al. Treatment with growth hormone increases lipoprotein(a) serum levels in children with chronic renal insufficiency (letter). Eur J Pediatr 1996: 155: 913-918.
135. LARON Z, WANG XL, KLINGER B, SILBERGELD A, WILCKEN DEL. Insulin-like growth factor 1 lowers serum lipoprotein(a) during long-term treatment of patients with Laron syndrome. Metabolism 1996
136. FINE RN, STABLEIN D, COHEN AH, TEJANI A. Recombinant human growth hormone post-renal transplantation in children: a randomized controlled study of NAPRTCS. Kidney Int 2002: 62: 688-696.
137. TONSHOFF B, HAFFNER D, ALBERS N, OFFNER G, MEHLS O. Predictors of the response to growth hormone in short prepubertal children post-renal transplant. Br J Clin Pract 1996: 85 (Suppl.): 34-37.